MariTide’s Switch Trial: What “Monthly” Actually Means, and What It Doesn’t
Amgen's MariTide has been covered widely as "the monthly weight-loss shot," but that shorthand glosses over the specific trial generating the most useful data right now: MARITIME-SWITCH, a study testing whether people already doing well on weekly semaglutide or tirzepatide can transition to MariTide on a much less frequent schedule. The trial itself doesn't test monthly dosing at all. This piece covers what MARITIME-SWITCH actually measures, why the dosing interval matters, and what the study can't tell us yet.
Key Takeaways
MariTide (maridebart cafraglutide, internal code AMG 133) is Amgen’s investigational antibody-peptide conjugate for obesity: a monoclonal antibody fragment that blocks the GIP receptor, physically linked to peptide segments that activate the GLP-1 receptor, the reverse mechanism from tirzepatide, which activates both receptors.
MARITIME-SWITCH, a roughly 300-patient Phase 3 trial disclosed by Amgen in an April 2026 earnings call, tests transitioning patients already stable on weekly semaglutide or tirzepatide to MariTide dosed every 8 weeks or quarterly, not monthly.
MariTide’s long half-life, roughly 21 days, is what makes infrequent dosing pharmacologically plausible in the first place; that same property is why Amgen is testing maintenance intervals longer than the once-monthly regimen used for treatment-naive patients in other trials.
MariTide is not FDA-approved. A regulatory filing is anticipated in late 2026 or early 2027 based on current industry reporting, with a possible launch in 2027 or 2028 if that filing succeeds.
As of this writing, there are no verified reports of a gray-market “research peptide” version of MariTide comparable to what exists for simpler compounds like retatrutide, plausibly because MariTide’s antibody-peptide conjugate structure requires biologic manufacturing capability that a typical peptide-synthesis operation isn’t equipped to replicate.
What Is MariTide, and How Is Its Mechanism Different?
MariTide is built differently from every other injectable weight-loss drug currently in the news. Semaglutide activates the GLP-1 receptor alone. Tirzepatide activates both the GLP-1 and GIP receptors together. MariTide does something structurally distinct: it pairs a monoclonal antibody fragment that blocks, rather than activates, the GIP receptor with peptide segments that activate the GLP-1 receptor, all conjugated into a single antibody-peptide molecule. That combination of GIP antagonism with GLP-1 agonism is the opposite pairing from tirzepatide’s dual-agonist approach, and it reflects a genuinely different scientific bet about how the two receptor systems interact in regulating body weight.
What Does the MARITIME-SWITCH Trial Actually Test?
This is the detail that most coverage compresses into “monthly.” MARITIME-SWITCH is a Phase 3 trial, disclosed by Amgen on an April 30, 2026 earnings call, enrolling roughly 300 patients who are already established on weekly semaglutide or weekly tirzepatide. The trial transitions those patients onto MariTide, but not on a monthly schedule: it tests dosing every 8 weeks or quarterly. The question the trial is actually designed to answer is narrower and more specific than “can MariTide replace a weekly shot”: it’s whether someone who has already achieved meaningful weight loss on a weekly drug can maintain that result while being dosed dramatically less often.
Why Does Every-8-Weeks or Quarterly Dosing Matter?
Dosing frequency is a real clinical and quality-of-life variable, not just a convenience footnote. A patient stable on a weekly injection has already absorbed the burden of frequent dosing into their routine; the question MARITIME-SWITCH asks is whether that burden can be reduced without losing ground on weight maintenance. This is only plausible because of MariTide’s pharmacology: its roughly 21-day half-life means the drug stays active in the body far longer between doses than semaglutide or tirzepatide do, which is the underlying reason Amgen can test intervals like every 8 weeks or quarterly at all, and it’s a different pharmacological property than what would be required to simply switch someone to a monthly version of the same class of drug.
What Does the Switch Trial Not Establish Yet?
It’s worth being precise about the trial’s limits. MARITIME-SWITCH is testing maintenance in patients who are already responding well to an existing weekly drug; it is not, by itself, a trial establishing MariTide’s effectiveness as a first-line treatment for someone starting from scratch, that evidence comes from Amgen’s separate treatment-naive obesity trials, which use a different (monthly) starting regimen. The switch trial also hasn’t reported results as of this writing; enrollment was still continuing as of September 2026. Until results are published, no one, including Amgen, can say definitively whether every-8-weeks or quarterly dosing actually maintains weight loss as well as staying on a weekly drug does.
Is MariTide FDA-Approved?
No. MariTide remains fully investigational. Based on current industry reporting, Amgen is expected to file for FDA approval in late 2026 or early 2027, with a possible launch in 2027 or 2028 if that filing is successful. Amgen has already signaled how central MariTide is to its obesity strategy: the company discontinued a separate, earlier-stage obesity candidate, AMG 513, in 2026, consolidating its pipeline around MariTide specifically. None of that changes MariTide’s current regulatory status: it is not available by prescription, and no switch protocol like the one being tested in MARITIME-SWITCH is available outside of the clinical trial itself.
What Do Earlier Phase 2 Results Show?
Amgen’s Phase 2 data, covering roughly 52 weeks, reported average weight loss up to approximately 20% at higher doses, a result broadly in the same range as the other next-generation obesity drugs covered elsewhere on this site. Side effects were common: more than 90% of patients on MariTide reported at least one adverse event, compared to a substantially lower rate on placebo, and the events were overwhelmingly gastrointestinal, nausea, vomiting, and constipation, generally described as mild to moderate, concentrated around the first dose, and diminishing with gradual dose escalation. That pattern is consistent with the broader GLP-1 drug class, though MariTide’s less frequent dosing means each individual dose may need to account for a longer stretch of time before the next one.
Is There a Gray Market for MariTide?
Not currently, at least not one with verified reports comparable to what exists for retatrutide, BPC-157, or other simpler research peptides sold online. There’s a plausible structural reason for that gap: MariTide isn’t a straightforward synthetic peptide that a peptide-synthesis lab can replicate. It’s an antibody-peptide conjugate, meaning it requires monoclonal antibody production, a biologic manufacturing process considerably more complex and expensive than standard peptide synthesis, before the peptide component is even attached. That doesn’t make an eventual gray-market version impossible, and the same “research chemical” labeling loophole covered elsewhere on this site could in principle be applied to it, but as of this writing, the manufacturing barrier appears to be a meaningful obstacle that hasn’t applied in the same way to simpler compounds.
The Bottom Line
MariTide is a genuinely different drug from semaglutide and tirzepatide, both in its GIP-blocking, GLP-1-activating mechanism and in the dosing intervals Amgen is actively testing. But “monthly” is an oversimplification of what’s actually being studied in MARITIME-SWITCH: that trial tests every-8-weeks or quarterly maintenance dosing specifically for patients already stable on a weekly drug, not a monthly starting regimen for everyone, and it hasn’t reported results yet. Until it does, and until the FDA completes its own review, MariTide’s real-world dosing schedule, and its actual availability, remain open questions rather than settled facts.
Comments